Orphan drug applications skyrocket as Big Pharma carves out niche

01/31/2013 | Wall Street Journal, The

Rare diseases are attracting renewed interest as multinational drugmakers seek to take advantage of easier approval pathways and high prices for orphan drugs. Firms including Sanofi, Pfizer and GlaxoSmithKlein are working on or have already secured approval for drugs that treat rare conditions. The progress in understanding the molecular base for these diseases has also spurred drugmakers' interest.

View Full Article in:

Wall Street Journal, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA